# Use patient organoids to check a cell therapy will work before infusing it

Source: https://onco.cc/ideas/idea-bio1-organoid-cell-therapy-potency/  
OnCo record `idea-bio1-organoid-cell-therapy-potency` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cell therapies are tested for purity and count, but not for whether they can actually kill that patient's tumour. Testing them against the patient's own mini-tumour would show this.

## Summary

Release criteria for CAR-T and TIL products measure viability, transduction and sterility, not tumour-specific cytotoxicity. Co-culturing an aliquot of the product with the patient's own organoid or tumour slice gives a functional potency assay with a killing readout. This could flag likely non-responders before lymphodepletion, and provide a comparator when choosing between products or targets.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Ex vivo killing of the patient's own organoid by the manufactured product predicts clinical response, and products failing a defined potency threshold have a markedly lower response rate.
- Rationale: Product potency varies widely and correlates with T-cell fitness in reported series; a patient-specific functional assay is the most direct measure and can be run during the manufacturing window.
- Proposed test: Prospective blinded correlation in 60 patients receiving CAR-T or TIL therapy, comparing organoid killing scores with response at three months.
- Maturity: speculative
- Actor: research

## Sources

- Bottleneck evidence (Lab models that fail to predict what happens in patients): Wong, Siah & Lo, Estimation of clinical trial success rates (Biostatistics 2019): https://doi.org/10.1093/biostatistics/kxx069

## Connected records

- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Patient-derived organoids](https://onco.cc/technologies/organoids/), [TIL therapy](https://onco.cc/technologies/til-therapy/)
- drugs: [Lifileucel](https://onco.cc/drugs/lifileucel/)
- companies: [Iovance Biotherapeutics](https://onco.cc/companies/iovance/)
- bottlenecks: [Lab models that fail to predict what happens in patients](https://onco.cc/bottlenecks/b-preclinical-models/), [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/)
- key papers: [Estimation of clinical trial success rates and related parameters](https://onco.cc/key-papers/paper-wong-biostatistics/)

---
JSON: https://onco.cc/api/v1/entities/idea-bio1-organoid-cell-therapy-potency.json